Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas
Open Access
- 4 March 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-9
- https://doi.org/10.1038/s41598-021-84606-x
Abstract
While prolactinoma patients have high bone turnover, current data are inconclusive when it comes to determining whether correction of hyperprolactinemia and associated hypogandism improves osteodensitometric data in men and women over the long term. In a large cohort of including 40 men and 60 women, we studied the long-term impact of prolactinoma treatment on bone mineral density (BMD) in men versus women, assessed adverse effects of a primary surgical or medical approach, and evaluated data for risk factors for impaired BMD at last follow-up using multivariate regression analyses. Median duration of follow-up was 79 months (range 13–408 months). Our data indicate that the prevalence of impaired BMD remained significantly higher in men (37%) than in women (7%, p < 0.001), despite the fact that hyperprolactinemia and hypogonadism are under control in the majority of men. We found that persistent hyperprolactinemia and male sex were independent risk factors for long-term bone impairment. Currently, osteoporosis prevention and treatment focus primarily on women, yet special attention to bone loss in men with prolactinomas is advised. Bone impairment as “end organ” reflects the full range of the disease and could become a surrogate marker for the severity of long-lasting hyperprolactinemia and associated hypogonadism.This publication has 68 references indexed in Scilit:
- Bone-Density Testing Interval and Transition to Osteoporosis in Older WomenThe New England Journal of Medicine, 2012
- Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive casesActa Endocrinologica, 2011
- Testosterone and the Male Skeleton: A Dual Mode of ActionJournal of Osteoporosis, 2011
- Evidence for direct effects of prolactin on human osteoblasts: Inhibition of cell growth and mineralizationJournal of Cellular Biochemistry, 2009
- Dual-Energy X-ray Absorptiometry Diagnostic Discordance Between Z-Scores and T-Scores in Young AdultsJournal of Clinical Densitometry, 2009
- Purposeful selection of variables in logistic regressionSource Code for Biology and Medicine, 2008
- Predictors of remission of hyperprolactinaemia after long‐term withdrawal of cabergoline therapyClinical Endocrinology, 2007
- When to discontinue treatment of prolactinoma?Nature Clinical Practice Endocrinology & Metabolism, 2006
- Standards and Guidelines for Performing Central Dual-Energy X-Ray Absorptiometry in Premenopausal Women, Men, and ChildrenA Report From the Canadian Panel† of the International Society of Clinical DensitometryJournal of Clinical Densitometry, 2004
- Sellar reconstruction with resorbable vicryl patches, gelatin foam, and fibrin glue in transsphenoidal surgery: a 10-year experience with 376 patientsJournal of Neurosurgery, 2000